Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Aventis HIV Dermal Filler Approval Precedes Broader Cosmetic Trial

This article was originally published in The Gray Sheet

  • News

Executive Summary

Dermik Laboratories expects to launch a clinical trial by year-end to assess its Sculptra injectable poly-L-lactic acid as a cosmetic filler for the general population

You may also be interested in...



BioForm Medical Does Not Expect Any Wrinkles In Upcoming Submission

BioForm Medical says it plans to submit a PMA for a new product to fill face wrinkles by the end of November

BioForm Medical Does Not Expect Any Wrinkles In Upcoming Submission

BioForm Medical says it plans to submit a PMA for a new product to fill face wrinkles by the end of November

Aventis/Dermik’s Facial Repair Device Gets Compassionate Panel Nod

FDA should actively restrict access to Aventis/Dermik Labs' Sculptra injectable facial restoration agent to patients with HIV-related lipoatrophy, according to FDA's General & Plastic Surgery Devices Panel

Table

View full table

Tags:
Latest Headlines

Second EU MDR Notified Body Designated In France

Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217

CDS Final Guidance Draws More Criticism, This Time From Congress

Alarming Rise Of Diabetes in Several US States, Study Shows

See All
UsernamePublicRestriction

Register

MT020677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By